Principal Investigator.
A Phase II Activity and Safety Study of IntraDose (Cisplatin/Epinephrine
Injectable Gel) when given in combination with Systemic Chemotherapy
Paclitaxel and Carboplatin in the Treatment of Patients with Squamous Cell
Carcinoma of the Head and Neck.
Co-Investigator. A
Phase IIA Study of the Efficacy and Tolerability of J-107088 in patients with
advances Squamous Cell Carinomas of the Head and Neck.
Co-Investigator. A
Phase III, Multicenter, Raandomized, Double-Blind, Placebo-Controlled Study of
Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia
Secondary to Radiation Therapy for Cancer in the Head and Neck Region.
Co-Investigator: Genetic Alterations in Oral
Cancer, funded by Smokeless Tobacco Research Council, Inc., January 1,
2000-December 31, 2002, $275,241.
Principal Recipient: Coping with Head and Neck Cancer: A
Guide for Patients and Families, funded by Pfizer Mini-Medical School Grant,
November 1999, $10,000.
Co-Principal Investigator. PG-010 A Phase I,
Pharmacokinetic Study of 9mg and 30mg IB-367 Comparing Antimicrobial
Activity in Patients who are Undergoing Radiation Therapy with or without
Concurrent Chemotherapy for Head and Neck Carcinoma, funded by PRA, Inc.,
August 1999, $18,125.
Co-Principal Investigator. MAB-9806-01 A Phase I/II Dose
Escalation Study of
Radioimmunotherapy Using In 111 and Yttrium Y 90 Labeled
LiLo-16.88, a Human Monoclonal Antibody Conjugate Administered by Direct
Intratumoral Injection in Patients with Recurrent Head and Neck Squamous
Cell Cancer, funded by Intracel Corporation, May 1999, $100,000.
Co-Principal Investigator. Genetic Alterations in Oral
Cancer, equally funded by College of Medicine and University Hospital, July
1998, $15,000
Principal Investigator: Randomized Trial Using Aspirin
for Premalignant Lesions, funded by American Cancer Society IRG-165h,
January 1997-January 1998, $11,750
Co-Principal Investigator: Protocol MAB-9706, A Clinical
Evaluation of the Safety and Therapeutic Potential of Human Monoclonal
Antibodies Administered by Direct Intratumoral Injection in Patients with
Head and Neck Squamous Cell Cancer, funded by PerImmune, Inc., November
1997, $64,000
Co-Principal Investigator: MAB-9510 Phase I-II Study of
Radioimmunoconjugate 111In Li Lo - 16.88: in Head and Neck Squamous Cell
Cancer, BB-IND 6310, $80,430.00
Co-Principal Investigator: MGA/09-054-191 9p21, 3p21 in
Premalignant Lesions of the Oral Cavity and Oropharynx, College of Dentistry
Research Seed Grant, November 1996-June 1997, $6000
Principal Investigator: Randomized Trial Using Aspirin
for Premalignant Lesions of the Head and Neck, funded by Nebraska Methodist
Hospital Foundation, July 1996, $10,000
Back to Top
Sullivan,
M., Gaebler, C., Beukelman, D., Mahanna, G., Marshall, J., Lyditt, D. & Lydiatt
WM:Impact of Palatal Prosthodontic Intervention on Communication
Performance of Patients=Maxillectomy Defects: A Multi-level Outcome Study.
Head and Neck.
2002; 24(6) 530-538
Bridge JA, Kanamori M, Ma Z, Pickering D, Hill DA, Lydiatt WM,
Lui MY, Colleoni GWB, Antonescu CR, Ladanyi M, Morris SW: Fusion of the ALK
Gene to the Clathrin Heavy Chain Gene, CLTC, in Inflammatory Myofibroblastic
Tumor. American Journal
of Pathology. 2001; 159(2):411-415.
Johnson PG, Robbins D, Lydiatt WM, Moore GF:
Salvage of an Infected Hydroxyapatite Cement Cranioplasty with Preservation
of the Implant Material. Otol Head and Neck Surgery.
2000; 123(4):515-7.
Lydiatt DD, Lydiatt WM,
Karrer FW, Grasz F: Tobacco Litigation and Legislation. Head
and Neck Surgery, October 2000.
Matamoros A, Lydiatt WM, Lydiatt DL, Mahoney E:
Pediatric Neck Masses: CT and MR Imaging. Applied Radiology, May 2000.
Weekly M, Lydiatt DD, Lydiatt WM, Baker SC:
Primary Cutaneous Adenoid Cystic Carcinoma Metastatic to Cervical Lymph
Nodes. Head and Neck, January 2000.
Cohen DM, Bhattacharyya I, Lydiatt WM:
Recalcitrant Oral Ulcers Caused by Calcium Channel Blockers: Diagnosis and
Treatment Considerations. JADA, 1999; 130:1611-1618.
Johnson P, Lydiatt DD, Baxter J, Hollins R, Lydiatt
WM: Microvascular Reconstruction of the Head and Neck After Tumor
Ablation. AORN Journal, 1999, 70:30-33.1.
Lydiatt DD, Lydiatt WM, Hollins RR, Friedman AC:
Free Fibula Options in the Patient with Failed Mandibular Reconstruction. Journal
of Maxillofacial Surgery, 1998; 56:444-446.
Lydiatt WM, Anderson PE, Bazzana T, Casale M,
Hughes CJ, Huvos AG, Lydiatt DD, Schantz, SP: Molecular Support for Field
Cancerization in the Head and Neck. Cancer, 1998, 82: 1376-1380.
Lydiatt WM, Davidson BJ, Schantz SP, Chaganti RSK.
9p21 deletion not involving CDKN2 correlates with recurrence in head and
neck cancer. Head and Neck, 1998, 20:113-8. 2.
Lydiatt WM, Lydiatt DD. Advances in the Surgical
Management of Carcinoma of the Oral Cavity. Oral and Maxillofacial
Surgery Clinics of North America, W.B. Sanders Co., Philadelphia.
August 1997.
Lydiatt WM, Cihak RA, Lydiatt DD, Bridge, JA:
Synovial Sarcoma of the Head and Neck: Chromosomal Translocation (X;18) as
a Diagnostic Aid. Head and Neck, 1997, 19:549-553.
Lydiatt WM, Shaha AR, Munshi I, Robbins R. Giant
Mediastinal Parathyroid Cyst Masquerading as a Substernal Goiter. Otolaryngology-Head
and Neck Surgery, 1997; 116:411-13.
Lydiatt WM, Shah JP, Lydiatt KM. Conservation
surgery for recurrent carcinoma of the glottic larynx. Am J Surg,
1996, l72:662-64.
Lydiatt WM, Kraus DH, Cordeiro PG, Hidalgo DA, Shah
JP. Posterior pharyngeal carcinoma resection with larynx preservation and
radial forearm free flap reconstruction:
a preliminary report. Head and Neck, 18:501-505,
1996.
Davidson BJ, Lydiatt WM, Abate MT, Schantz SP,
Chaganti RSK. Cyclin D1
abnormalities correlate with risk factor exposure in
head and neck squamous cell carcinoma. Head and Neck, 18:512-521,
1996.
Lydiatt WM, Schantz SP. Biological staging of head
and neck cancer and its role in developing effective treatment strategies.
Cancer and Metastasis Reviews, 15:11-25, 1996.
McGuire M, Lydiatt W, Trambert R, Shaha A,
Schantz S. Head and neck screening day for the community. Journal New
York Academy of Science, 1995 December.
Shah JP, Lydiatt WM. Treatment of cancer of the
head and neck. CA J Clin, 1995; 45:352-368.
Shah JP, Lydiatt WM. Buccal Mucosa, Alveolus,
Retromolar Trigone, Floor of Mouth, Hard Palate, and Tongue Tumors.
Chapter in Comprehensive Management of Head and Neck Tumors, Thawley,
Panje, Batsakis and Lindberg eds, August, 1995.
Lydiatt WM, Murty VVVS, Davidson BJ, Xu L, Dyomina
K, Sacks PG, Schantz SP, Chaganti RSK. Homozygous deletions and loss of
expression of the CDKN2 gene occurs frequently in head and neck squamous
cell carcinoma cell lines but infrequently in primary tumors. Genes
Chromosom Cancer, 1995; 13:94-98.
Book
& Book Chapters:
Co-author
chapter entitled The Larynx: Early Stage Disease@ published by American Cancer
Society in Atlas of Clinical Oncology, 2001.
Co-author
chapter entitled “Glottic Carcinoma” to be published in Otolaryngology
and Facial Plastic Surgery, e-Medicine, 2001.
Co-author
chapter entitled “Penetrating Injuries of the Neck” to be published in Otolaryngology
and Facial Plastic Surgery, e-Medicine, 2001.
Co-author
chapter entitled “Early Laryngeal Cancer” to be published by American Cancer
Society in Atlas of Clinical Oncology, 2001.
Co-author
book entitled “Cancers of the Mouth & Throat.
A Patient’s Guide to Treatment”, published by Addicus Book, October
2000.
Back to Top